Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Datar-Cancer-Genetics

More Like This

PR Newswire associated0

Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

PR Newswire associated0

Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalized Treatment of Difficult-to-Treat Cancers.

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

PR Newswire associated0

Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor

HER2DX studies presented at ASCO.

ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer